Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
MUMBAI, India and NAPLES, Fla. and SAN DIEGO, July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women's Health. Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Lupin divests women’s health specialty business in US to Evofem for $84 million
Evofem Biosciences, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel.
The FDA has taken Evofem Biosciences to task for allegedly playing fast and loose with the facts, accusing the biotech of overstating the benefits of its contraceptive Phexxi in a digital patient brochure.
Evofem Biosciences last week received an untitled letter from the FDA, which cited “misleading” benefits in a marketing brochure for its contraceptive gel brand Phexxi.